Impact of Crohn’s Disease on the Survival of Patients with Small-Bowel Adenocarcinoma in Korea: A Bicenter Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Owing to the low prevalence of small-bowel adenocarcinoma (SBA), data on the impact of Crohn’s disease (CD) on the survival of patients with SBA are lacking. Therefore, we investigated this issue in this study. Methods: In this bicenter cohort study, patients with histologically confirmed SBA were retrospectively enrolled and classified into two groups: sporadic SBA and CD-associated SBA. Patients with duodenal SBA were excluded. Overall survival, disease-free survival, and factors associated with survival were analyzed. Results: Of 128 patients with SBA, 115 had sporadic SBA and 13 had CD-associated SBA. Ileal involvement and poorly differentiated tumors were more common in the CD-associated SBA group than in the sporadic SBA group (ileal involvement, 53.8% vs 22.6%; poor differentiation, 46.2% vs 14.8%; both p<0.05). In survival analysis, overall survival showed no statistical difference between the sporadic SBA and CD-associated SBA groups (p=0.370). However, when stratified by stage, the adjusted overall survival of the CD-associated SBA group was lower in patients with an advanced disease stage (p=0.029). Disease-free survival showed the same tendency, albeit without clinical significance (p=0.097). CD (hazard ratio [HR], 2.308; p=0.047), older age (≥65 yr) at SBA diagnosis (HR, 2.766; p=0.001), and stage III/IV disease (HR, 3.151; p<0.001) were factors associated with mortality. Conclusions: The overall survival of patients with CD-associated SBA did not differ from that of patients with sporadic SBA. However, as CD is an independent risk factor for mortality, vigilant surveillance in high-risk patients may be crucial.
Abstract
Background/Aims: Owing to the low prevalence of small-bowel adenocarcinoma (SBA), data on the impact of Crohn’s disease (CD) on the survival of patients with SBA are lacking. Therefore, we investigated this issue in this study. Methods: In this bicenter cohort study, patients with histologically confirmed SBA were retrospectively enrolled and classified into two groups: sporadic SBA and CD-associated SBA. Patients with duodenal SBA were excluded. Overall survival, disease-free survival, and factors associated with survival were analyzed. Results: Of 128 patients with SBA, 115 had sporadic SBA and 13 had CD-associated SBA. Ileal involvement and poorly differentiated tumors were more common in the CD-associated SBA group than in the sporadic SBA group (ileal involvement, 53.8% vs 22.6%; poor differentiation, 46.2% vs 14.8%; both p<0.05). In survival analysis, overall survival showed no statistical difference between the sporadic SBA and CD-associated SBA groups (p=0.370). However, when stratified by stage, the adjusted overall survival of the CD-associated SBA group was lower in patients with an advanced disease stage (p=0.029). Disease-free survival showed the same tendency, albeit without clinical significance (p=0.097). CD (hazard ratio [HR], 2.308; p=0.047), older age (≥65 yr) at SBA diagnosis (HR, 2.766; p=0.001), and stage III/IV disease (HR, 3.151; p<0.001) were factors associated with mortality. Conclusions: The overall survival of patients with CD-associated SBA did not differ from that of patients with sporadic SBA. However, as CD is an independent risk factor for mortality, vigilant surveillance in high-risk patients may be crucial.
참고문헌 (43)
- 홍승욱, "The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia", Intestinal research, 18(4), pp.345~346 (2020), 대한장연구학회[DOI]
- Annese V, "European evidencebased consensus : inflammatory bowel disease and malignancies", J Crohns Colitis, 9, pp.945~965 (2015)
- Arshdeep Singh, "Use of thiopurines in inflammatory bowel disease: an update", Intestinal research, 20(1), pp.11~30 (2022), 대한장연구학회[DOI]
- 오규만, "Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?", Intestinal research, 18(3), pp.245~246 (2020), 대한장연구학회[DOI]
- Palascak-Juif V, "Small bowel adenocarcinoma in patients with Crohn’s disease compared with small bowel adenocarcinoma de novo", Inflamm Bowel Dis, 11, pp.828~832 (2005)
- Shaukat A, "Crohn’s disease and small bowel adenocarcinoma : a population-based case-control study", Cancer Epidemiol Biomarkers Prev, 20, pp.1120~1123 (2011)
- Cahill C, "Small bowel adenocarcinoma and Crohn’s disease : any further ahead than 50 years ago?", World J Gastroenterol, 20, pp.11486~11495 (2014)
- Bojesen RD, "Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology : a population-based study", Clin Gastroenterol Hepatol, 15, pp.1900~1907 (2017)
- Fields AC, "Small bowel adenocarcinoma : is there a difference in survival for Crohn’s versus sporadic cases?", J Crohns Colitis, 14, pp.303~308 (2020)
- Wieghard N, "Prognosis of small bowel adenocarcinoma in Crohn’s disease compares favourably with de novo small bowel adenocarcinoma", Colorectal Dis, 19, pp.446~455 (2017)
- Munkholm P, "Intestinal cancer risk and mortality in patients with Crohn’s disease", Gastroenterology, 105, pp.1716~1723 (1993)
- Kaerlev L, "Medical risk factors for small-bowel adenocarcinoma with focus on Crohn disease : a European population-based case-control study", Scand J Gastroenterol, 36, pp.641~646 (2001)
- Jess T, "Mortality and causes of death in Crohn’s disease : follow-up of a population-based cohort in Copenhagen County, Denmark", Gastroenterology, 122, pp.1808~1814 (2002)
- Solem CA, "Small intestinal adenocarcinoma in Crohn’s disease : a casecontrol study", Inflamm Bowel Dis, 10, pp.32~35 (2004)
- Jess T, "Intestinal and extra-intestinal cancer in Crohn’s disease : follow-up of a population-based cohort in Copenhagen County, Denmark", Aliment Pharmacol Ther, 19, pp.287~293 (2004)
- Jess T, "Increased risk of intestinal cancer in Crohn’s disease : a metaanalysis of population-based cohort studies", Am J Gastroenterol, 100, pp.2724~2729 (2005)
- Canavan C, "Meta-analysis : colorectal and small bowel cancer risk in patients with Crohn’s disease", Aliment Pharmacol Ther, 23, pp.1097~1104 (2006)
- Laukoetter MG, "Intestinal cancer risk in Crohn’s disease : a meta-analysis", J Gastrointest Surg, 15, pp.576~583 (2011)
- Elriz K, "Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn’s disease : a prospective observational study", Inflamm Bowel Dis, 19, pp.1823~1826 (2013)
- Axelrad JE, "Inflammatory bowel disease and risk of small bowel cancer : a binational population-based cohort study from Denmark and Sweden", Gut, 70, pp.297~308 (2021)
- Schuman BM, "Adenocarcinoma arising in an excluded loop of ileum", N Engl J Med, 283, pp.136~137 (1970)
- Greenstein AJ, "Cancer in Crohn’s disease : the danger of a by-passed loop", Am J Gastroenterol, 64, pp.122~124 (1975)
- Senay E, "Small bowel carcinoma in Crohn’s disease : distinguishing features and risk factors", Cancer, 63, pp.360~363 (1989)
- Lashner BA, "Risk factors for small bowel cancer in Crohn’s disease", Dig Dis Sci, 37, pp.1179~1184 (1992)
- Barwood N, "Case report : adenocarcinoma arising in a Crohn’s stricture of the jejunum", J Gastroenterol Hepatol, 14, pp.1132~1134 (1999)
- Jaskowiak NT, "Adenocarcinoma at a strictureplasty site in Crohn’s disease : report of a case", Dis Colon Rectum, 44, pp.284~287 (2001)
- Partridge SK, "Small bowel adenocarcinoma at a strictureplasty site in a patient with Crohn’s disease : report of a case", Dis Colon Rectum, 47, pp.778~781 (2004)
- Menon AM, "Adenocarcinoma of the small bowel arising from a previous strictureplasty for Crohn’s disease : report of a case", Dis Colon Rectum, 50, pp.257~259 (2007)
- Egan L, "Non-colorectal intestinal tract carcinomas in inflammatory bowel disease : results of the 3rd ECCO Pathogenesis Scientific Workshop(II)", J Crohns Colitis, 8, pp.19~30 (2014)
- Piton G, "Risk factors associated with small bowel adenocarcinoma in Crohn’s disease : a casecontrol study", Am J Gastroenterol, 103, pp.1730~1736 (2008)
- Collier PE, "Small intestinal adenocarcinoma complicating regional enteritis", Cancer, 55, pp.516~521 (1985)
- Nicholl MB, "Small bowel adenocarcinoma : understaged and undertreated?", Ann Surg Oncol, 17, pp.2728~2732 (2010)
- Widmar M, "Small bowel adenocarcinoma in Crohn’s disease", J Gastrointest Surg, 15, pp.797~802 (2011)
- "Small bowel adenocarcinoma (version 1.2022)" (2022)[URL]
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Amin MB, "AJCC Cancer Staging Manual" (2017), Springer
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- Park SH, "A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015", J Crohns Colitis, 13, pp.1410~1417 (2019)
- Kenji Watanabe, "Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion", Intestinal research, 18(4), pp.347~354 (2020), 대한장연구학회[DOI]
- Giuseppe Cicero, "Crohn’s disease at radiological imaging: focus on techniques and intestinal tract", Intestinal research, 19(4), pp.365~378 (2021), 대한장연구학회[DOI]
- Jeon Seong Ran, "Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study", Gut and Liver, 15(3), pp.375~382 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- 이유진, "Is Paradigm for the Role of Balloon-Assisted Enteroscopy Changing in Crohn’s Disease?", Gut and Liver, 15(3), pp.325~326 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Liao X, "Clinicopathological and molecular characterisation of Crohn’s disease-associated small bowel adenocarcinomas", J Crohns Colitis, 14, pp.287~294 (2020)